R & D

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

 This material is intended to notify the press release issued on April 26 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.